The share of generics in total pharmaceutical supply in Germany rose further: from 67.1% in 2009 to 78.7% in 2019. This emerges from the analysis provided in "Generics in Figures 2019", published by the Pro Generics Association on June 19, 2020.
In absolute terms, the consumption of generics within statutory health insurance in 2019 amounted to 35 billion daily therapy doses. In 2018 this indicator reached 34.1 billion; in 2009, it totaled 24.9 billion.
Between 2009 and 2019, the consumption of patented pharmaceuticals fell from 4.2 billion to 2.2 billion daily therapy doses. The use of patent-free first-party products dropped from 8 billion to 7.2 billion of daily therapy doses. And the consumption of biosimilars rose from 0.01 billion to 0.09 billion of daily therapy doses.
Despite the high use in healthcare, the share of generics in health insurance costs is comparatively low: in 2019, it amounted to less than 5.8 billion euros. In 2009 this indicator reached 4.3 billion euros.
In contrast, the pharmaceutical costs of patented medicines rose from 7.4 billion to 12.2 billion euros in the same period. The cost of patent-free first-party products rose from 7.3 billion to 9.5 billion euros. And the cost of biosimilars rose from 0.05 billion to 0.92 billion euros.
The full details in German can be found here
. The "Generics in Figures 2019" report in German can be found here
to our newsletter delivered every second week not to miss important reimbursement information.